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TO THE EDITOR
We thank Ulmer and Fierlbeck (2011)
for their interest in our work. We fully
agree that the detection and monitoring
of circulating melanoma cells is a
rapidly expanding field of potential
clinical relevance for cutaneous mela-
noma patients. In the specific clinical
context of cutaneous melanoma, PCR is
by far the most commonly used techni-
que for the detection of circulating
tumor cells (CTC) and multimarker
quantitative PCR is considered to be
the state-of-the-art quantitative method.
In this respect, the 2004 study by Ulmer
et al. (2004) is of interest, but not of
fully appreciable clinical impact for the
following reasons. First, the series
lumped together, for unknown reasons,
164 patients with cutaneous or uveal
melanoma with either localized or
metastatic disease, but the number of
cutaneous melanoma patients analyzed
was not reported. As cutaneous and
uveal melanoma are distinct tumor
entities clinically, morphologically, ge-
netically, or prognostically, the signifi-
cance of the data is questionable.
Second, CTC were enriched by immu-
nomagnetic cell sorting using a single-
murine monoclonal antibody against
the melanoma-associated chondroitin
sulfate proteoglycan (MCSP). MCSP is
expressed in over 85% of primary and
metastatic melanoma lesions, with si-
milar levels of expression among lenti-
go maligna, nodular, and superficial
spreading melanomas. However, a
more variable and generally lower
expression has been reported in acral
lentiginous melanomas, spanning from
30% (Kageshita et al., 1993) to 53.6%
(Nishi et al., 2010). Thus, MCSP-nega-
tive melanoma circulating cells may
escape detection by the method de-
scribed by Ulmer et al. (2004). In
addition, MCSP is not detectable in
cells of hematopoietic origin, including
healthy peripheral blood cells (Campoli
et al., 2004; Kitago et al., 2009).
Thus, the observation by Ulmer et al.
(2004) that granulocytes showed posi-
tive staining for MCSP (as illustrated in
Figure 1c) should have raised doubts
concerning the specificity of the mono-
clonal antibody. Third, to prove the
malignant nature of the MPCS-positive
cells, genomic aberrations were demon-
strated in isolated CTC from seven
patients by single-cell comparative
genomic hybridization. Although of
interest, such high-throughput, high-
cost analysis may be suitable for
research settings, but its application in
a routine clinical setting is questionable.
Currently, there is no consensus on
the best method to identify CTC in
cutaneous melanoma, and only a case-
by-case comparison of techniques may
demonstrate which method is superior
in terms of specificity and sensitivity.
The choice of appropriate markers is a
challenge, as antigens exclusively ex-
pressed by CTC and not shared by other
circulating non-tumor or blood cells are
scarce. In our study (De Giorgi et al.,
2010), we chose the CTC analysis
associated with immunochemistry and
molecular analysis because this repre-
sents the gold standard for routine
diagnosis of cancer. It should be noted
also that melanocytic differentiation
biomarkers such as MART-1 and
HMB-45 are commonly used to detect
both primary and metastatic melanoma,
including lymph nodal metastasis.
Ulmer and Fierlbeck (2011) are
not convinced that the cells stained by
S-100 protein and HMB-45, reported in
Figure 1, fulfill the morphological criteria
for tumor cells. We disagree with their
comment because the nucleocytoplas-
mic features of the cell reported in
Figure 1 are similar to those of the mela-
noma cell line SK-Mel 28 and, more
importantly, because the intensity of the
staining and absence of background
staining are of sufficient diagnostic value.
Similarly, the ‘‘non-stained debris’’
around the HMB45-positive melanoma
cells are simply fibrin depositions.
Morphological criteria for the identi-
fication of CTC (e.g., cell size X16mm,
nucleocytoplasmic ratioX50%, irregu-
lar nuclear shape, hyperchromatic nu-
cleus, and basophilic cytoplasm) were
originally defined for identification
of epithelial cells using the method of
isolation by size of epithelial tumor
cells (Vona et al., 2000). Whereas
epithelial cells in the isolation by size
of epithelial tumour cells assay tend to
form cell aggregates (Pinzani et al.,
2006), in our experience CTC from
cutaneous melanoma usually appear
as isolated individual cells and are
recognizable as either nonpigmented
large epithelioid or smaller cells with a
roundish to oval shape and indented
nucleus. In the case of cells of uncertain
morphological recognition, including
small size cells, filters underwent
further immunohistochemical identifi-
cation with S-100 protein, HMB-45,
MART-1, or CD45 to support an accu-
rate identification of melanoma cells.
More than one marker may be required
to conclusively identify cells on the
filters as CTC, as loss of antigen
expression may occur.
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